류마티스 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Rheumatology Therapeutics Market size is expected to reach USD 70.83 Billion in 2034 from USD 54.86 Billion (2025) growing at a CAGR of 2.88% during 2026-2034.

The Global Rheumatology Therapeutics Market is expanding due to the increasing prevalence of autoimmune and inflammatory disorders such as rheumatoid arthritis and lupus. Aging populations and rising awareness about early diagnosis contribute significantly to growth. Advancements in biologic therapies and targeted treatments have improved patient outcomes. Expanding healthcare access and improved diagnostic capabilities further strengthen the market.

Key drivers include growing adoption of biologics and biosimilars for managing chronic inflammatory conditions. Rising research investments in immunology and personalized medicine enhance therapeutic innovation. Increasing healthcare expenditure and supportive reimbursement policies also drive demand. Collaborations between pharmaceutical companies and research institutes accelerate product development and commercialization.

Looking forward, the market is expected to benefit from advancements in precision medicine and novel drug delivery systems. Emerging economies with improving healthcare infrastructure will offer significant growth opportunities. Continued focus on reducing disease progression and improving quality of life will shape future therapies. As innovation continues in immunology research, the rheumatology therapeutics market is poised for sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Disease Modifying Anti-rheumatic Drugs (DMARDs)
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others

By Disease Indication

• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Route of Administration

• Parenteral Route
• Oral Route
• Topical

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Merck Co Inc, AbbVie Inc, BristolMyers Squibb Company, Pfizer Inc, Takeda Pharmaceutical Company Limited, Amgen Inc, Genentech Inc, Novartis AG, Johnson Johnson Innovative Medicine, F HoffmannLa Roche AG, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Disease Modifying Anti-rheumatic Drugs (DMARDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Uric Acid Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Osteoarthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gout Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Psoriatic Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ankylosing Spondylitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Route Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Route Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Disease Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Disease Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Disease Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Disease Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Disease Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL RHEUMATOLOGY THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Merck & Co. Inc
  • 10.2.2 AbbVie Inc
  • 10.2.3 Bristol-Myers Squibb Company
  • 10.2.4 Pfizer Inc
  • 10.2.5 Takeda Pharmaceutical Company Limited
  • 10.2.6 Amgen Inc
  • 10.2.7 Genentech Inc
  • 10.2.8 Novartis AG
  • 10.2.9 Johnson & Johnson Innovative Medicine
  • 10.2.10 F. Hoffmann-La Roche AG
  • 10.2.11 Sanofi